View Item 

Show simple item record

Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitorsâ A retrospective analysis
dc.contributor.authorCarcao, M.
dc.contributor.authorShapiro, A.
dc.contributor.authorStaber, J. M.
dc.contributor.authorHwang, N.
dc.contributor.authorDruzgal, C.
dc.contributor.authorLieuw, K.
dc.contributor.authorBelletrutti, M.
dc.contributor.authorThornburg, C. D.
dc.contributor.authorAhuja, S. P.
dc.contributor.authorMorales‐arias, J.
dc.contributor.authorDumont, J.
dc.contributor.authorMiyasato, G.
dc.contributor.authorTsao, E.
dc.contributor.authorJain, N.
dc.contributor.authorPipe, S. W.
dc.date.accessioned2018-04-04T18:49:22Z
dc.date.available2019-05-13T14:45:25Zen
dc.date.issued2018-03
dc.identifier.citationCarcao, M.; Shapiro, A.; Staber, J. M.; Hwang, N.; Druzgal, C.; Lieuw, K.; Belletrutti, M.; Thornburg, C. D.; Ahuja, S. P.; Morales‐arias, J. ; Dumont, J.; Miyasato, G.; Tsao, E.; Jain, N.; Pipe, S. W. (2018). "Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitorsâ A retrospective analysis." Haemophilia 24(2): 245-252.
dc.identifier.issn1351-8216
dc.identifier.issn1365-2516
dc.identifier.urihttps://hdl.handle.net/2027.42/142910
dc.publisherWiley Periodicals, Inc.
dc.subject.otherrescue therapy
dc.subject.otherrecombinant factor VIII Fc fusion protein
dc.subject.otherretrospective chart review
dc.subject.otherinhibitor
dc.subject.otherimmune tolerance induction
dc.subject.otherhaemophilia A
dc.titleRecombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitorsâ A retrospective analysis
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142910/1/hae13413.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142910/2/hae13413_am.pdf
dc.identifier.doi10.1111/hae.13413
dc.identifier.sourceHaemophilia
dc.identifier.citedreferenceMalec LM, Journeycake J, Ragni MV. Extended halfâ life factor VIII for immune tolerance induction in haemophilia. Haemophilia. 2016; 22: e552 â e554.
dc.identifier.citedreferenceDiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007; 13 ( Suppl 1 ): 1 â 22.
dc.identifier.citedreferenceOldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017; 377: 809 â 818.
dc.identifier.citedreferenceWight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia. 2003; 9: 436 â 463.
dc.identifier.citedreferenceCoppola A, Margaglione M, Santagostino E, et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with highâ responding inhibitors. J Thromb Haemost. 2009; 7: 1809 â 1815.
dc.identifier.citedreferenceGringeri A, Musso R, Mazzucconi MG, et al. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia. 2007; 13: 373 â 379.
dc.identifier.citedreferenceHay CR, DiMichele DM; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012; 119: 1335 â 1344.
dc.identifier.citedreferenceHaya S, Lopez MF, Aznar JA, Batlle J; Spanish Immune Tolerance Group. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia. 2001; 7: 154 â 159.
dc.identifier.citedreferenceJimenezâ Yuste V, Oldenburg J, Rangarajan S, Kurth MH, Bozzo J, Santagostino E. Clinical overview of Fanhdi/Alphanate (plasmaâ derived, VWFâ containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors. Haemophilia. 2016; 22: e71 â e74.
dc.identifier.citedreferenceKreuz W, Escuriola Ettingshausen C, Vdovin V, Zozulya N, Plyushch O, Svirin P, et al. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study. Haemophilia. 2016; 22: 87 â 95.
dc.identifier.citedreferenceNakar C, Mancoâ Johnson MJ, Lail A, et al. Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres. Haemophilia. 2015; 21: 365 â 373.
dc.identifier.citedreferenceOldenburg J, Jimenezâ Yuste V, Peiroâ Jordan R, Aledort LM, Santagostino E. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWFâ containing plasmaâ derived FVIII concentrate. Haemophilia. 2014; 20: 83 â 91.
dc.identifier.citedreferenceDiMichele DM, Kroner BL; North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost. 2002; 87: 52 â 57.
dc.identifier.citedreferenceAntun A, Monahan PE, Mancoâ Johnson MJ, et al. Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study. J Thromb Haemost. 2015; 13: 1980 â 1988.
dc.identifier.citedreferenceValentino LA, Kempton CL, Kruseâ Jarres R, et al. US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors. Haemophilia. 2015; 21: 559 â 567.
dc.identifier.citedreferenceWalsh CE, Jimenezâ Yuste V, Auerswald G, Grancha S. The burden of inhibitors in haemophilia patients. Thromb Haemost. 2016; 116 ( Suppl 1 ): S10 â S17.
dc.identifier.citedreferenceMahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014; 123: 317 â 325.
dc.identifier.citedreferenceShapiro AD, Mahlangu JN, Perry D, et al. Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in Aâ LONG study subjects with severe haemophilia A. Haemophilia. 2017; 23: 392 â 399.
dc.identifier.citedreferenceNolan B, Mahlangu J, Perry D, et al. Longâ term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia. 2016; 22: 72 â 80.
dc.identifier.citedreferenceYoung G, Mahlangu J, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015; 13: 967 â 977.
dc.identifier.citedreferenceDe Groot AS, Moise L, McMurry JA, et al. Activation of natural regulatory T cells by IgG Fcâ derived peptide â Tregitopesâ . Blood. 2008; 112: 3303 â 3311.
dc.identifier.citedreferenceGupta N, Culina S, Meslier Y, et al. Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance. Sci Transl Med. 2015; 7: 275ra21.
dc.identifier.citedreferenceGeorgescu MLT, Sponagle K, Hebert K, et al. Factor VIII tolerance induction in haemophilia a mice via transplacental transfer of recombinant factor VIII Fc. J Thromb Haemost. 2015; 13: 1 â 997.
dc.identifier.citedreferenceKrishnamoorthy S, Liu T, Drager D, et al. Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice. Cell Immunol. 2016; 301: 30 â 39.
dc.identifier.citedreferenceKisâ Toth K, Simpson A, Henry K, Loh C. Immunology studies on recombinant factor VIII Fc fusion protein. Res Pract Thromb Haemost. 2017; 1 ( Suppl 1 ): 1 â 1451.
dc.identifier.citedreferenceJimenezâ Yuste V, Oldenburg J, Rangarajan S, Peiroâ Jordan R, Santagostino E. Longâ term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasmaâ derived FVIII/VWF product: the longâ term ITI study. Haemophilia. 2016; 22: 859 â 865.
dc.identifier.citedreferenceRocino A, Franchini M, Coppola A. Treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII/IX. J Clin Med. 2017; 6: 46 â 64.
dc.identifier.citedreferenceSu JZJ, Buckley B, Rising T, Hou Q, Jain N. The immune tolerance induction factor utilizations and costs for the management of male hemophiliaâ A patients who developed inhibitors. Am Soc Hematol. 2016; 128: P4758.
dc.identifier.citedreferenceMariani G, Kroner B; Immune Tolerance Study Group. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica. 2001; 86: 1186 â 1193.
dc.identifier.citedreferenceMinno GD, Santagostino E, Pratt K, Königs C. New predictive approaches for ITI treatment. Haemophilia. 2014; 20: 27 â 43.
dc.identifier.citedreferenceKempton CL, White GC 2nd. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood. 2009; 113: 11 â 17.
dc.identifier.citedreferenceCallaghan MU, Rajpurkar M, Chitlur M, Warrier I, Lusher J. Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans? Haemophilia. 2011; 17: 483 â 489.
dc.identifier.citedreferenceGroomes CL, Gianferante DM, Crouch GD, Parekh DS, Scott DW, Lieuw K. Reduction of factor VIII inhibitor titers during immune tolerance induction with recombinant factor VIIIâ Fc fusion protein. Pediatr Blood Cancer. 2016; 63: 922 â 924.
dc.identifier.citedreferenceSu JZJ, Buckley B, Hou Q, Jain N. Utilizations and costs of bypass therapies for the management of hemophilia A patients with inhibitors. Haemophilia. 2017; 23: 87 â 88.
dc.identifier.citedreferenceMannucci PM, Tuddenham EG. The hemophiliasâ from royal genes to gene therapy. N Engl J Med. 2001; 344: 1773 â 1779.
dc.identifier.citedreferenceLieuw K. Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches? J Blood Med. 2017; 8: 67 â 73.
dc.identifier.citedreferenceBerntorp E, Shapiro AD. Modern haemophilia care. Lancet. 2012; 379: 1447 â 1456.
dc.identifier.citedreferencePasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017; 377: 819 â 828.
dc.identifier.citedreferencePeyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet (London, England). 2016; 388: 187 â 197.
dc.identifier.citedreferenceGouw SC, van der Bom JG, Marijke van den Berg H. Treatmentâ related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007; 109: 4648 â 4654.
dc.identifier.citedreferenceDarby SC, Keeling DM, Spooner RJ, et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977â 99. J Thromb Haemost. 2004; 2: 1047 â 1054.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hae13413.pdf
Size:
357.8KB
Format:
PDF
View/Open
Name:
hae13413_am.pdf
Size:
531.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.